Outcome of a multicenter treatment program including autologous or allogeneic bone marrow transplantation for de novo acute myeloid leukemia

European Journal of Haematology

Volumn 58, Issue 4, 1997, Pages 233-240

  Wahlin, Anders ^a   Brinch, Lorentz ^b   Hörnsten, Per ^a   Evensen, Stein A ^b   Öberg, Gunnar ^c   Simonsson, Bengt ^c   Hedenus, Michael ^d  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d Central Hospital   (Sweden)

Author keywords

acute myeloid leukemia; allogeneic BMT; autologous BMT; chemotherapy; survival

Indexed keywords

AMSACRINE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 0031009025     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1997.tb01660.x     Document Type: Article

References (44)

1. BATTISTA R, BASSAN R, D'EMILIO A, et al. Short-term remission induction and consolidation therapy for adult acute myelogenous leukemia. Hematol Oncol 1991: 9: 4 3-52.
2. MAYER RJ, DAVIS RB, SCHIFFER CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994: 331: 896-903.
3. BÜCHNER T, URBANITZ D, HIDDEMANN W, et al. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol 1985: 3: 1583-1589.
4. WAHLIN A, HÖRNSTEN P, JONSSON H. Remission rate and survival in acute myeloid leukemia: impact of selection and chemotherapy. Eur J Haematol 1991: 46: 240-247.
5. CASSILETH PA, LYNCH E, HINES JD, et al. Varying intensity of postremission therapy in acute myeloid leukemia. Blood 1992: 79: 1924-1930.
6. EVENSEN SA, BRINCH L, STAVEM P, TÖNNFJORD G. Survival in 91 adults with acute myelogenous leukemia treated with 1-6 intensive courses of chemotherapy. J Intern Med 1992: 232: 433-437.
7. WHEATLEY K. Meta-analysis of randomized trials of idarubicin (IDAR) or mitozantrone (MITO) versus daunorubicin(DNR) as induction therapy for acute myeloid leukemia (AML). Blood 1995: 86 (suppl.1): 434a.
8. BENNET JM, CATOVSKY D, DANIEL MT, et al. Proposals for the classification of the acute leukemias: French-American-British (FAB) Co-operative Group. Br J Haematol 1976: 33: 451-458.
9. BENNET JM, CATOVSKY D, DANIEL MT, et al. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. Ann Intern Med 1985: 103: 460-462.
10. BENNET JM, CATOVSKY D, DANIEL MT, et al. Proposed revised criteria for for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med 1985: 103: 620-625.
11. CHESON BD, CASSILETH PA, HEAD DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990: 8: 813-819.
12. BRINCH L, EVENSEN SA, STAVEM P. Leukemia in the central nervous system. Acta Med Scand 1988: 224: 173-178.
13. TUTSCHKA PJ, COPELAN EA, KLEIN JP. Bone marrow transplantation following a new busulfan and cyclophosphamide regimen. Blood 1987: 70: 1382-1388.
14. GORIN NC. Collection, manipulation and freezing of haemopoietic stem cells. Clin Haematol 1986: 15: 19-48.
15. KAPLAN EL, MEIER P. Nonparametric estimation from incomplete observations. J Am Stat Ass 1958: 53: 457-481.
16. PETO R, PIKE MC, ARMITAGE P, et al. Design and analysis of randomized clinical trials requiring prolonged observations of each patient. Br J Cancer 1977: 35: 1-39.
17. DICK FR, ARMITAGE JO, BURNS CP. Diagnostic concurrence in the subclassification of adult acute leukemia using the French-American-British criteria. Cancer 1982: 49: 916-920.
18. CAREY RW, RIBAS-MUNDO M, ELLISON RR, et al. Comparative study of cytosine arabinoside therapy alone and combined with thioguanine, mercaptopurine, or daunorubicin in acute myelocytic leukemia. Cancer 1975: 36: 1560-1566.
19. WIERNIK PH, GLIDEWELL OJ, HOAGLAND HC, et al. A comparative trial of daunorubicin, cytosine arabinoside, and thioguanine, and a combination of the three agents for the treatment of acute myelocytic leukemia. Med Ped Oncol 1979: 6: 261-277.
20. STONE RM, MAYER RJ. Treatment of the newly diagnosed adult with de novo acute myeloid leukemia (1993) Hematol Oncol Clin North Am 1993: 7: 47-64.
21. GALE RP, FOON KA, CLINE MJ, ZIGHELBOIM. Intensive chemotherapy for acute myelogenous leukemia. Ann Intern Med 1981: 94: 753-757.
22. PHILLIPS GL, REECE DE, SHEPHERD JD, et al. High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults. Blood 1991: 77: 1429-1435.
23. BERMAN E, HELLER G, SANTORSA J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991: 77: 1666-1674.
24. VOGLER WR, VELEZ-GARCIA E, WEINER RS, et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group study. J Clin Oncol 1992: 10: 1103-1111.
25. MITUS AJ, MILLER KB, SCHENKEIN DP, et al. Improved survival for patients with acute myelogenous leukemia. J Clin Oncol 1995: 13: 560-569.
26. DILLMAN RO, DAVIS RB, GREEN MR, et al. A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. Blood 1991: 78: 2520-2526.
27. BISHOP JF, MATTHEWS JP, YOUNG GA, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996: 87: 1710-1717.
28. KANTARJIAN HM, KEATING MJ, WALTERS RS, MCCREDIE KB, BODEY GP, FREIREICH EJ. Early intensification and short-term maintenance chemotherapy does not prolong survival in acute myelogenous leukemia. Cancer 1986: 58: 1603-1608.
29. PREISLER HD, ANDERSON K, RAI K, CUTTNER J, DUPRE E, HOLLAND JF. The frequency of long-term remission in patients with acute myelogenous leukemia treated with conventional maintenance chemotherapy: a study of 760 patients with a minimal follow-up time of 6 years. Br J Haematol 1989: 71: 189-194.
30. BENNET JM, ANDERSEN JW, CASSILETH PA. Long-term survival in acute myelogenous leukemia: the Eastern Cooperative Oncology Group (ECOG) experience. Leukemia Res 1991: 15: 223-227.
31. LAMVIK J, DYBEDAL I, HAMMERSTRÖM J, WAAGE A. Acute leukemia in middle Norway 1984-88. Leuk Lymph 1994: 16: 65-71.
32. HEWLETT J, KOPECKY KJ, HEAD D, et al. A prospective evaluation of the roles of allogeneic marrow transplantation and low-dose monthly maintenance chemotherapy in the treatment of adult acute myelogenous leukemia (AML): a Southwest Oncology Group study. Leukemia 1995: 9: 562-569.
33. BERMAN E, LITTLE C, GEE T, O'REILLY R, CLARKSON B. Reasons that patients with acute myelogenous leukemia do not undergo allogeneic bone marrow transplantation. N Engl J Med 1992: 326, 156-160.
34. FRASSONI F, LABOPIN M, GLUCKMAN E, et al. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time - a report of the acute leukemia working party of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Trans 1996: 17: 13-18.
35. BURNETT AK, TANSEY P, WATKINS R, et al. Transplantation of unpurged autologous bone-marrow in acute myeloid leukaemia in first remission. Lancet 1984: 2, 1068-1070.
36. GORIN NC, AEGERTER P, AUVERT B, et al. Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: a European survey of the role of marrow purging. Blood 1990: 75: 1606-1614.
37. MCMILLAN AK, GOLDSTONE AH, LINCH DC, et al. High-dose chemotherapy and autologous bone marrow transplantation in acute myeloid leukemia. Blood 1990: 76: 480-488.
38. ZITTOUN RA, MANDELLI F, WILLEMZE R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995: 332: 217-223.
39. LAPORTE JP, DOUAY L, LOPEZ M, et al. One hundred twenty-five adult patients with primary acute leukemia autografted with marrow purged by mafosfamide: a 10-year single institution experience. Blood 1994: 84: 3810-3818.
40. SELVAGGI KJ, WILSON JW, MILLS LE, et al. Improved outcome for high-risk acute myeloid leukemia patients using autologous bone marrow transplantion and monoclonal antibody-purged bone marrow. Blood 1994: 83: 1698-1705.
41. LJUNGMAN P, DE WITTE T, VERDONCK L, et al. Bone marrow transplantation for acute myeloblastic leukemia: an EBMT Leukemia Working Party prospective analysis from HLA-typing. Br J Haematol 1993: 84: 61-66.
42. FRASSONI F, LABOPIN M, GLUCKMAN E, et al. Are patients with acute leukemia, alive and well 2 years post bone marrow transplantation cured? A European survey. Leukemia 1994: 8: 924-928.
43. CARELLA AM, FRASSONI F, DAMASIO E, et al. Allogeneic versus autologous marrow transplantation for patients with acute myeeloid leukemia in first marrow remission. An update of the Genoa experience with 159 patients. Leukemia 1992: 6: 78-81.
44. CAHN JY, LABOPIN M, MANDELLI F, et al. Autologous bone marrow transplantation for first remission acute myeloblastic leukemia in patients older than 50 years: a retrospective analysis of the European Bone Marrow Transplant Group. Blood 1995: 85: 575-579.